Advertisement

Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease

Published:November 20, 2020DOI:https://doi.org/10.1053/j.gastro.2020.11.038

      Background & Aims

      Pregnant women with inflammatory bowel disease (IBD) may require biologic or thiopurine therapy to control disease activity. Lack of safety data has led to therapy discontinuation during pregnancy, with health repercussions to mother and child.

      Methods

      Between 2007 and 2019, pregnant women with IBD were enrolled in a prospective, observational, multicenter study across the United States. The primary analysis was a comparison of 5 outcomes (congenital malformations, spontaneous abortions, preterm birth, low birth weight, and infant infections) among pregnancies exposed vs unexposed in utero to biologics, thiopurines, or a combination. Bivariate analyses followed by logistic regression models adjusted for relevant confounders were used to determine the independent effects of specific drug classes on outcomes of interest.

      Results

      Among 1490 completed pregnancies, there were 1431 live births. One-year infant outcomes were available in 1010. Exposure was to thiopurines (n = 242), biologics (n = 642), or both (n = 227) vs unexposed (n = 379). Drug exposure did not increase the rate of congenital malformations, spontaneous abortions, preterm birth, low birth weight, and infections during the first year of life. Higher disease activity was associated with risk of spontaneous abortion (hazard ratio, 3.41; 95% confidence interval, 1.51–7.69) and preterm birth with increased infant infection (odds ratio, 1.73; 95% confidence interval, 1.19–2.51).

      Conclusions

      Biologic, thiopurine, or combination therapy exposure during pregnancy was not associated with increased adverse maternal or fetal outcomes at birth or in the first year of life. Therapy with these agents can be continued throughout pregnancy in women with IBD to maintain disease control and reduce pregnancy-related adverse events. ClinicalTrials.gov, Number: NCT00904878.

      Graphical abstract

      Keywords

      Abbreviations used in this paper:

      ASQ3 (Ages and Stages Questionnaire, 3rd edition), CI (confidence interval), HR (hazard ratio), IBD (inflammatory bowel disease), LBW (low birth weight), OR (odds ratio), SAB (spontaneous abortion), TNF (tumor necrosis factor), UC (ulcerative colitis)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ananthakrishnan A.N.
        • Kaplan G.A.
        • Ng S.C.
        Changing global epidemiology of inflammatory bowel diseases-sustaining healthcare delivery into the 21st century.
        Clin Gastroenterol Hepatol. 2020; 18: 1252-1260
        • Mahadevan U.
        • Sandborn W.J.
        • Li D.K.
        • et al.
        Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California.
        Gastroenterology. 2007; 133: 1106-1112
        • Norgard B.
        • Hundborg H.H.
        • Jacobsen B.A.
        • et al.
        Disease activity in pregnant women with Crohn's disease and birth outcomes: a regional Danish cohort study.
        Am J Gastroenterol. 2007; 102: 1947-1954
        • Polifka J.E.
        • Friedman J.M.
        Teratogen update: azathioprine and 6-mercaptopurine.
        Teratology. 2002; 65: 240-261
        • Casanova M.J.
        • Chaparro M.
        • Domenech E.
        • et al.
        Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease.
        Am J Gastroenterol. 2013; 108: 433-440
        • Goldstein L.H.
        • Dolinsky G.
        • Greenberg R.
        • et al.
        Pregnancy outcome of women exposed to azathioprine during pregnancy.
        Birth Defects Res A Clin Mol Teratol. 2007; 79: 696-701
        • Julsgaard M.
        • Christensen L.A.
        • Gibson P.R.
        • et al.
        Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection.
        Gastroenterology. 2016; 151: 110-119
        • Mahadevan U.
        • Wolf D.C.
        • Dubinsky M.
        • et al.
        Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.
        Clin Gastroenterol Hepatol. 2013; 11 (quiz e24): 286-292
        • Lichtenstein G.R.
        • Rutgeerts P.
        • Sandborn W.J.
        • et al.
        A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease.
        Am J Gastroenterol. 2012; 107: 1051-1063
        • Luu M.
        • Benzenine E.
        • Doret M.
        • et al.
        Continuous anti-TNFalpha use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French National Health Insurance Database (EVASION).
        Am J Gastroenterol. 2018; 113: 1669-1677
        • Nguyen G.C.
        • Seow C.H.
        • Maxwell C.
        • et al.
        The Toronto Consensus statements for the management of inflammatory bowel disease in pregnancy.
        Gastroenterology. 2016; 150: 734-757.e1
        • Mahadevan U.
        • Robinson C.
        • Bernasko N.
        • et al.
        Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group.
        Gastroenterology. 2019; 156: 1508-1524
        • van der Woude C.J.
        • Ardizzone S.
        • Bengtson M.B.
        • et al.
        The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease.
        J Crohns Colitis. 2015; 9: 107-124
        • Pedersen N.
        • Bortoli A.
        • Duricova D.
        • et al.
        The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women.
        Aliment Pharmacol Ther. 2013; 38: 501-512
        • Harvey R.F.
        • Bradshaw J.M.
        A simple index of Crohn's-disease activity.
        Lancet. 1980; 1: 514
        • Walmsley R.S.
        • Ayres R.C.
        • Pounder R.E.
        • et al.
        A simple clinical colitis activity index.
        Gut. 1998; 43: 29-32
        • Squires J.T.E.
        • Bricker D.
        • Potter L.
        ASQ-3 User's Guide.
        Paul H Brookes Publishing Co, Baltimore2009
        • Wang S.L.
        • Ohrmund L.
        • Hauenstein S.
        • et al.
        Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum.
        J Immunol Methods. 2012; 382: 177-188
        • Marchioni R.M.
        • Lichtenstein G.R.
        Tumor necrosis factor-alpha inhibitor therapy and fetal risk: a systematic literature review.
        World J Gastroenterol. 2013; 19: 2591-2602
        • Nielsen O.H.
        • Loftus Jr., E.V.
        • Jess T.
        Safety of TNF-alpha inhibitors during IBD pregnancy: a systematic review.
        BMC Med. 2013; 11: 174
        • Schnitzler F.
        • Fidder H.
        • Ferrante M.
        • et al.
        Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy.
        Inflamm Bowel Dis. 2011; 17: 1846-1854
        • Broms G.
        • Granath F.
        • Ekbom A.
        • et al.
        Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy.
        Clin Gastroenterol Hepatol. 2016; 14: 234-241.e1-5
        • Kammerlander H.
        • Nielsen J.
        • Kjeldsen J.
        • et al.
        The effect of disease activity on birth outcomes in a nationwide cohort of women with moderate to severe inflammatory bowel disease.
        Inflamm Bowel Dis. 2017; 23: 1011-1018
        • Nasef N.A.
        • Ferguson L.R.
        Inflammatory bowel disease and pregnancy: overlapping pathways.
        Transl Res. 2012; 160: 65-83